Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00008216 · ClinicalTrials.gov registry record
Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer
A clinical trial, sponsored by Columbia University.
- Terminated
- Registry status
- 48
- Enrollment target
NCT00008216 is a clinical trial that was terminated before completion, run by Columbia University. The registered enrollment target is 48 participants.
The verdict
NCT00008216 was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- 48 participants
- Enrollment target
Study Summary
RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. PURPOSE: This phase II trial is studying the effectiveness of donor peripheral blood stem cell transplant in treating patients with hematologic cancer.
Interventions
- PROCEDURE Peripheral Blood Stem Cell Transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 1996-07 |
| Est. Completion | 2009-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00008216
The ClinicalTrials.gov registry entry for NCT00008216 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Peripheral Blood Stem Cell Transplantation is the first listed.
NCT00008216 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00008216 about?
NCT00008216 is a clinical study titled "Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer". RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into ...
What is the current status of trial NCT00008216?
This trial is currently terminated. The enrollment target is 48 participants. The study started on 1996-07. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00008216?
The interventions under investigation include: Peripheral Blood Stem Cell Transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00008216?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.